EISO

Santalis Pharmaceuticals, fully owned subsidiary of TFS, has started patient enrolment in a Phase ll trial of 10% East Indian Sandalwood Oil (EISO) serum formulation to treat mild to moderate plaque psoriasis.

Psoriasis is an autoimmune disease that causes raised, red, scaly patches to appear on the skin.

The disease usually affects the outside of the elbows, knees or scalp, though it can appear on any location.

The trial is a single-centre, open label, efficacy and tolerability proof of concept study and will enrol at least 15 patients to look at preliminary efficacy after 28 days of twice a day treatment.

TFS’ pharmaceutical grade EISO has been demonstrated to inhibit a wide range of inflammatory and proliferative pathways believed to underlie the Psoriasis condition, including down-regulation of PDE4 activity.

Santalis Pharmaceuticals CEO Paul Castella said: "Australia is an important clinical development location for Santalis, as EISO is already a listed medicine with the Therapeutic Goods Administration.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"Australia is an important clinical development location for Santalis, as EISO is already a listed medicine with the Therapeutic Goods Administration."

"Therefore, unlike many other drugs in development, we can quickly complete clinical studies and learn more about EISO’s clinical utility.

"In addition, we can then present this data to other regulatory authorities such as the FDA and EU, speeding up the regulatory process in these countries."

The company noted that Indian sandalwood is a tradable commodity spanning thousands of years, but is now endangered due to the illegal harvest of wild trees across the globe.

Resultantly, Indian sandalwood has become the world’s most expensive tropical hardwood. It is globally used as an ingredient in fragrances, cosmetics and toiletries, Indian consumer products and is also used for traditional medicinal purposes such as Ayurvedic and Chinese medicine.


Image: Psoriasis is a disease that causes raised, red, scaly patches to appear on the skin. Photo: courtesy of US Military.